SBIR/STTR Research Award
Combinatorial rat panels that genetically screen anthrax
Award amount
$312,536Program and phase
SBIR · Phase IAward year
2003Award details
- Awarding agency
- Department of Health and Human Services
- Branch
- National Institutes of Health
- Recipient company
- PHYSIOGENIX, INC.
- Proposal award date
- Not reported
- Contract end date
- Not reported
- UEI
- Not reported
- Solicitation number
- Not reported
- Topic code
- Not reported
Research abstract
DESCRIPTION (provided by applicant): The recent anthrax-related events have revealed the need to fill gaps in the knowledge base that compromise our response to a bioterrorist attack using Category A pathogens like Bacillus anthracis. As with most biological systems, there is tremendous diversity in response to pathogens. This SBIR Phase I project will test for diversity in host response to anthrax lethal toxin (LeTx). The investigators will identify and incorporate this diversity into a PathoGenix panel to: (1) mimic a genetically diverse, human population as the target in a bioterrorist attack; (2) be used as a sensitive screen for susceptible genotypes; and (3) identify intracellular pathways for therapeutic intervention. First, candidate rat strains will be selected based on the haplotype of anthrax-related genes using in silico tools. Second, in vivo and in vitro susceptibility to anthrax LeTx will be quantified followed by establishment of combinatorial breeding pairs. Third, the effects of LeTx will be measured in the panel, which enables localization of the gene region responsible for resistance or susceptibility. Decoding these data will begin to define the genomic contribution of the host-pathogen relationship. The goal in this project is to validate a new panel of rats for detecting the genetic effects of anthrax LeTx.
Technology keywords
Not reported